AI-Driven Antiviral Drug Development

Exscientia developed AI-driven solutions for antiviral drug discovery, particularly demonstrated during the COVID-19 pandemic. The company received funding from the COVID-19 Therapeutics Accelerator (backed by the Gates Foundation, Wellcome, and Mastercard) to design virus protease inhibitors using their AI platform. Exscientia's approach delivered optimized compounds fulfilling complex design goals faster and more effectively than conventional methods. The AI platform's ability to process vast chemical spaces enabled rapid identification of antiviral candidates. Beyond COVID-19, Exscientia applied similar AI approaches to other viral diseases including those affecting respiratory systems. Note: Exscientia merged with Recursion in 2024, combining two leading AI drug discovery companies.